CAS Medical Systems Inc : October 11 CASMED to Exhibit FORE-SIGHT ELITE" Cerebral Oximeter at American Society of Anesthesiologists Meeting October 12-16 in San Francisco

CASMED to Exhibit FORE-SIGHT ELITE™ Cerebral Oximeter
at American Society of Anesthesiologists Meeting October 12-16 in San Francisco

Branford, Conn. (October 11, 2013) - CAS Medical Systems, Inc. (NASDAQ: CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, is exhibiting its next generation FORE-SIGHT ELITE™ Cerebral Oximetry product at the American Society of Anesthesiologists (ASA) Annual Meeting, being held October 12-16, 2013, at the Moscone Center in San Francisco. Company representatives will be on hand at Booth No. 1027 to demonstrate the improved features and benefits of the ELITE.

"The theme of this years ASA annual meeting - 'Global Partners in Quality Outcomes and Patient Safety' - certainly is in keeping with the role cerebral oximetry plays in a surgical setting, and several presentations during the event reflect increasing recognition of the risk of oxygen desaturation and the importance of cerebral monitoring," said Thomas M. Patton, President and Chief Executive Officer of CASMED. "With several thousand anesthesiologists expected to attend the meeting, it is an excellent opportunity to continue educating the clinical community and expand our market opportunity."

The FORE-SIGHT ELITE is lighter and more portable than the prior model and includes several important new features for customers, such as ability to monitor four channels of patient information; a larger, higher contrast viewing screen; and intuitive touch-screen controls. A revolutionary system using five wavelengths of light to interrogate tissue under the sensor allows the ELITE to measure oxygenation at levels of accuracy previously not seen.

In addition to the eight courses and sessions being offered on different applications and aspects of cerebral oximetry and brain monitoring, the following posters will be presented on Sunday, October 13:

Cerebral Oximetry and Recovery in Thoracic Surgery, Monique Roberts, et.al., Icahn School of Medicine at Mount Sinai, NYC, NY, USA (A2030). This study shows that inter-operative cerebral desaturations for patients undergoing thoracic surgery (which occurred in 45% of the patients studied) had slower physiologic, cognitive, and emotional recoveries, and were more likely to suffer from delirium post-operatively.

Multimodal Blood Conservation Reduces Intraoperative Transfusion in a Community- Based Cardiac Surgery Practice, Brooker, et.al., Memorial Healthcare System, Hollywood, FL, USA (A2275.) This report shows that using FORE-SIGHT as a guide to trigger blood transfusions, within a wider program to limit blood product usage, resulted in an 82% reduction in units of blood per patient.

About CASMED® - Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For further information regarding CASMED, visit the Company's website at www.casmed.com.

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2012, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.